Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B

Robert Perrillo, Maria Buti, Francois Durand, Michael Charlton, Adrian Gadano, Guido Cantisani, Che‐Chuan Loong, Kimberly Brown, Wenhua Hu, Juan Carlos Lopez‐Talavera, Cyril Llamoso – 21 June 2013 – For patients undergoing liver transplantation (LT) for hepatitis B virus (HBV)–related liver disease, the current standard of care for preventing reinfection of the allograft is nucleoside analogue therapy combined with hepatitis B immune globulin (HBIG).

Subscribe to